Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: Evidence for common founders and independent mutations

Human Mutation

Volumn 11, Issue 6, 1998, Pages 424-431

  Pollock, Pamela M ^a   Spurr, Nigel ^b   Bishop, Tim ^b   Newton Bishop, Julia ^b   Gruis, Nelleke ^c   Van Der Velden, Pieter A ^c   Goldstein, Alisa M ^d   Tucker, Margaret A ^d   Foulkes, William D ^e   Barnhill, Ray ^f   Haber, Daniel ^g   Fountain, Jane ^h   Hayward, Nicholas K ^a,i  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f HARVARD UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

CDKN2A; Familial; Founder; Melanoma; Mutation

Indexed keywords

ARTICLE; CELL CYCLE G1 PHASE; FAMILIAL DISEASE; GENE DUPLICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GERM LINE; HAPLOTYPE; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; TANDEM REPEAT;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FOUNDER EFFECT; GENETIC MARKERS; GENOTYPE; GERM-LINE MUTATION; GERMANY; GREAT BRITAIN; HAPLOTYPES; MELANOMA; MULTIGENE FAMILY; SKIN NEOPLASMS;

EID: 7144229363     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.0.CO;2-2     Document Type: Article

References (41)

1. Amos W, Sawcer SJ, Feakes RW, Rubinsztein DC (1996) Microsatellites show mutational bias and heterozygote instability. Nature Genet 13:390-391.
2. Borg A, Johansson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, Olsson H, et al. (1996) Novel Germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 56:2497-2500.
3. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, et al. (1995) Frequency of homozygous deletions at p16/CDKN2 in primary human tumours. Nature Genet 11:210-212.
4. Castellano M, Pollock P, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 57:4868-4865.
5. Ciotti P, Strigini P, Bianchiscarra G (1996) Familial melanoma and pancreatic cancer. N Engl J Med 334:469-470.
6. Dracopoli NC, Fountain JW (1996) CDKN2A mutations in melanoma. Cancer Surv 26:115-131.
7. Fitzgerald MG, Harkin DP, Silia-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, et al. (1996) Prevelance of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma. Analysis of a clinic based population. Proc Natl Acad Sci USA 93:8541-8545.
8. Flores JF, Walker GJ, Glendening MJ, Haluska FG, Castesana JS, Rubio M-P, et al. (1996) Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032.
9. Flores JF, Pollock P, Walker GJ, Glendening JM, Lin A, Palmer JM, Walters MK, et al. (1997) Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15:2999-3005.
10. Foulkes W, Flanders TY, Pollock PM, Hayward NK (1997) The CDKN2A (p16) gene and human cancer. Mol Med 3:5-20.
11. Ghiorzo P, Mantelli M, Ciotti P, Ferrari C, Cafiero F, Grammatico P, Catricala C, et al. (1996) Italian melanoma prone families.analysis of CDKN2A/p16 mutations and linkage to 9p21 Am J Hum Genet 59 (suppl): A68.
12. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin D, Fontaine LS, et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970-974.
13. Gruis N, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR (1995a) CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169-177.
14. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldbaus J, Kamb A, Bergman W, et al. (1995b) Homozygotes for CDKN2A (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353.
15. Hayward, NK (1996) The current situation with regard to human melanoma and genetic inferences. Curr Opin Oncol 8:136-142.
16. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark Jr WH, et al. (1994) Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
17. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, et al. (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
18. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, et al. (1994b) Analysis of the p16 gene (CDKN2A) as a candidate for the chromosome 9p melanoma susceptability locus. Nature Genet 8:22-26.
19. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625.
20. Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, et al. (1995) CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067.
21. Liu L, Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ (1997) Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosom Cancer 18:1-3.
22. Luca M, Xie S, Gutman M, Huang S, Bar-Eli M (1995) Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: Relevance to tumor growth and metastasis. Oncogene 11:1399-1402.
23. MacGeoch C, Newton Bishop JA, Btaille V, Bishop DT, Frischauf A-M, Meloni R, Cuzick J, et al. (1994) Genetic heterogeneity in familial melanoma. Hum Mol Genet 3:2195-2200.
24. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995-2997.
25. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, Luxford C, et al. (1993) Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 53:96-104.
26. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
27. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, et al. (1994) Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4, in melanoma. Cancer Res 54:5269-5272.
28. Ohta M, Berd D, Shimuzu M, Nagai H, Cotticelli M-G, Mastrangelo M, Shields JA, et al (1996) Deletion mapping of Chromosome region 9p21-11 surounding the CDKN2A locus in melanoma Int J Cancer 65:762-767.
29. Parry D, Peters G (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16:3844-3852.
30. Platz A, Ringborg U, Lagerlöf B, Lundqvist E, Sevigny P Iganäs M (1996) Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. Br J Cancer 73:344-348.
31. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, et al. (1997) Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89:697-702.
32. Pollock PM, Yu F, Qiu L, Parsons PG, Hayward NK (1995) Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11:663-668.
33. Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosom Cancer 15:77-88.
34. Primmer CR, Samo N, Moller AP (1996) Directional evolution in germline microsatellite mutations. Nature Genet 13:391-393.
35. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclinD/CDK4. Nature 366:704-707.
36. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Devel 9:1149-1163.
37. Stone S, Jiang P, Dayanath P, Tavtigian SV, Katcher H, Parry D, Peters G, et al. (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988-2994.
38. Sun S, Pollock PM, Liu L, Karimi S, Jothy S, Milner BJ, Renwick A, et al. (1997) CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer 73:531-536.
39. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, et al. (1995) Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 10:1845-1852.
40. Weber JL, Wong C (1993) Mutation of human short tandem repeats. Hum Mol Genet 8:1123-1128.
41. Whelan AJ, Bartsch D, Goodfellow PJ (1995) A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2A tumor-suppressor gene. N Engl J Med 333:975-977.